|
|
 Previous Article | Table of Contents | Next Article 
Bone Resorption in Multiple Myeloma and in Monoclonal Gammopathy of Undetermined Significance: Quantification by Urinary Pyridinium Cross-Links of Collagen
Martin Pecherstorfer,
Markus J. Seibel,
Henning W. Woitge,
Eva Horn,
Judith Schuster,
Jane Neuda,
Peter Sagaster,
Horst Köhn,
Peter Bayer,
Daniel Thiébaud, and
Heinz Ludwig
From the First Department of Medicine and Medical Oncology, Department of Nuclear Medicine, and Central Laboratory, Wilhelminenspital, Vienna, Austria; Department of Medicine I (Endocrinology and Metabolism), University of Heidelberg Medical School, Heidelberg, Germany; and Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
To quantify osseous breakdown in multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), and benign osteoporosis, we measured urinary levels of pyridinium cross-links of collagen in 50 patients with newly diagnosed and untreated MM, 40 patients with MGUS, 40 untreated patients with osteoporotic vertebral fractures, and 64 healthy adults. Ion-paired, reverse-phase high-performance liquid chromatography (HPLC) was used to measure total urinary excretion of pyridinoline (h-PYD) and deoxypyridinoline (h-DPD). Urinary excretion of free immunoreactive deoxypyridinoline (i-DPD) was determined with an enzyme immunoassay. MM patients had significantly (P < .0001) higher levels of h-PYD, h-DPD, and i-DPD than the healthy adults, patients with MGUS, or patients with osteoporosis. The MGUS and osteoporosis groups presented with elevated (P < .05) levels of urinary pyridinium cross-links when compared with healthy controls. In 20 MM patients who subsequently received chemotherapy, the percent changes in i-DPD did not correlate with the changes in the monoclonal protein. In one of three patients experiencing a transition of initial MGUS into stage I MM, i-DPD increased above the upper limit of the normal range. In 13 patients with stable MGUS, i-DPD remained normal in repeated measurements. Based on the upper limits of the normal range, the sensitivity of urinary pyridinium cross-links in stage I and II MM was low (<50%), but it was between 78% (h-DPD) and 93% (i-DPD) in stage III MM. Specificity in patients with MGUS was between 87% (h-PYD) and 97% (h-DPD). In conclusion, determining the urinary excretion of pyridinium cross-links seems to be a promising noninvasive and thus easily repeatable method for evaluating the actual degree of osseous breakdown. Although measurement of pyridinium cross-link levels is not useful in discriminating patients with MGUS from early-stage myeloma patients, determination of i-DPD levels may contribute importantly to clinical guidance, since increased i-DPD levels seem to identify patients who are particularly likely to benefit from osteoclast-inhibiting drugs such as bisphosphonates. The fact that in a number of patients paraprotein concentrations and i-DPD levels did not change in parallel but instead diverged strongly after chemotherapy might explain the observation that bone lesions sometimes progress even in patients who achieve complete remission.
Blood, Vol. 90 No. 9 (November 1), 1997:
pp. 3743-3750
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. R. Berenson, O. Yellin, R. V. Boccia, M. Flam, S.-F. Wong, O. Batuman, M. M. Moezi, D. Woytowitz, H. Duvivier, Y. Nassir, et al.
Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss
Clin. Cancer Res.,
October 1, 2008;
14(19):
6289 - 6295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapoor
TGF-beta 1 and urinary excretion of pyridinium crosslinks: two often overlooked risk factors for assessing risk of progression in patients with monoclonal gammopathy of undetermined significance
Haematologica,
March 1, 2008;
93(3):
e38 - e38.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zheng, H. Zhou, J. R.K. Modzelewski, R. Kalak, J. M. Blair, M. J. Seibel, and C. R. Dunstan
Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone
Cancer Res.,
October 1, 2007;
67(19):
9542 - 9548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, A. Rapoport, R. Fenton, N. Gahres, E. Sausville, R. Ord, et al.
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
J. Clin. Oncol.,
February 20, 2006;
24(6):
945 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Fohr, C. R. Dunstan, and M. J. Seibel
Markers of Bone Remodeling in Metastatic Bone Disease
J. Clin. Endocrinol. Metab.,
November 1, 2003;
88(11):
5059 - 5075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Jakob, I. Zavrski, U. Heider, M. Bollow, C.-O. Schulz, C. Fleissner, J. Eucker, R. Michael, B. Hamm, K. Possinger, et al.
Serum Levels of Carboxy-terminal Telopeptide of Type-I Collagen Are Elevated in Patients with Multiple Myeloma Showing Skeletal Manifestations in Magnetic Resonance Imaging but Lacking Lytic Bone Lesions in Conventional Radiography
Clin. Cancer Res.,
August 1, 2003;
9(8):
3047 - 3051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers
Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline
Clin. Chem.,
February 1, 2002;
48(2):
220 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. W. Woitge, E. Horn, A. V. Keck, B. Auler, M. J. Seibel, and M. Pecherstorfer
Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis
Clin. Chem.,
April 1, 2001;
47(4):
686 - 693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Clark, A. J. Flory, E. M. Ion, B. E. Woodcock, B. H. Durham, and W. D. Fraser
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma
Blood,
October 15, 2000;
96(8):
2697 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Rosano, R. T. Peaston, H. G. Bone, H. W. Woitge, R. M. Francis, and M. J. Seibel
Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation
Clin. Chem.,
October 1, 1998;
44(10):
2126 - 2132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
